Objectives To explore the risk factors for, and clinical outcomes in men who have sex with men (MSM) prescribed HIV postexposure prophylaxis following sexual exposure (PEPSE) at sexual health clinics (SHCs) in England. Methods National STI surveillance data were extracted from the genitourinary medicine clinic activity dataset (GUMCADv2) for 2011-2014. Quarterly and annual trends in the number of episodes where PEPSE was prescribed were analysed by gender and sexual risk. Risk factors associated with being prescribed PEPSE among MSM attendees were explored using univariable and multivariable logistic regression. Subsequent HIV acquisition from 4 months after initiating PEPSE was assessed using multivariable Cox proportional hazards models, stratified by clinical risk profiles. Results During 2011-2014, there were 24 004 episodes where PEPSE was prescribed at SHCs, of which 69% were to MSM. The number of episodes where PEPSE was prescribed to MSM increased from 2383 in 2011 to 5944 in 2014, and from 1384 to 2226 for heterosexual men and women. 15% of MSM attendees received two or more courses of PEPSE. Compared with MSM attendees not prescribed PEPSE, MSM prescribed PEPSE were significantly more likely to have been diagnosed with a bacterial STI in the previous 12 months (adjusted OR (95% CI)-gonorrhoea: 11.6 (10.5 to 12.8); chlamydia: 5.02 (4.46 to 5.67); syphilis: 2.25 (1.73 to 2.93)), and were more likely to subsequently acquire HIV (adjusted HR (aHR) (95% CI) -single PEPSE course: 2.54 (2.19 to 2.96); two or more PEPSE courses: aHR (95% CI) 4.80 (3.69 to 6.25)). The probability of HIV diagnosis was highest in MSM prescribed PEPSE who had also been diagnosed with a bacterial STI in the previous 12 months (aHR (95% CI): 6.61 (5.19 to 8.42)). Conclusions MSM prescribed PEPSE are at high risk of subsequent HIV acquisition and our data show further risk stratification by clinical and PEPSE prescribing history is possible, which might inform clinical practice and HIV prevention initiatives in MSM.
INTRODUCTION
Postexposure prophylaxis following sexual exposure (PEPSE) is a potential method to prevent HIV infection. Current UK guidelines recommend that PEPSE, consisting of a 28-day course of antiretroviral therapy (Truvada (emtricitabine/tenofovir) and raltegravir) is offered to individuals who present within 72 hours of a defined risk exposure such as receptive unprotected anal intercourse (UAI) with a partner of unknown HIV status and from a known risk-group. 1 An HIV test is performed at baseline to rule out undiagnosed HIV infection, and a follow-up HIV test is performed 8-12 weeks postexposure. 1 Prospective randomised controlled trials (RCTs) to measure the efficacy of PEPSE are not ethically justifiable. 1 Consequently, there is a lack of evidence on the clinical effectiveness of PEPSE, and current UK guidelines draw on observational studies, animal studies and an understanding of the biology of HIV transmission. 1 The guidelines also state that other HIV prevention strategies should be prioritised, such that PEPSE is considered only where these have failed. 1 In the UK, men who have sex with men (MSM) are the population most at risk of acquiring HIV, accounting for over half (55%; 3360) of all new HIV diagnoses reported in 2014. The number of HIV diagnoses annually in MSM has shown a steadily rising trend over the past decade, which can be explained by increases in HIV testing as well as high levels of ongoing HIV transmission. 2 3 We analysed PEPSE prescribing in sexual health clinics (SHCs) in England using national surveillance data to understand better the role of PEPSE in HIV prevention, including any future preexposure prophylaxis (PrEP) policy, and to inform clinical decision making and resource allocation. We have described recent trends in PEPSE prescribing in SHCs and explored the risk factors for, and subsequent HIV diagnoses in MSM attendees prescribed PEPSE.
METHODS

Data source
Data were extracted from the genitourinary medicine clinic activity dataset (GUMCADv2), a patient-level dataset containing information on STI diagnoses and services provided by all genitourinary medicine (GUM) and integrated GUM/sexual and reproductive health services in England (referred to as SHCs). Clinical data are reported using national Sexual Health and HIV Activity Property Type (SHHAPT) codes and each attendance includes information on patient demographics (gender, age, sexual orientation, self-reported ethnicity and country of birth) and area of residence. 4 The national SHHAPT code for PEPSE ('PEPS') was introduced on 1 January 2011. Attendances by the same individual can be linked within SHCs (but not between clinics), enabling the identification of repeat visits and subsequent clinical diagnoses. 4 
Study population
All HIV-negative (defined as no prior HIV diagnosis-related SHHAPT code) attendees aged 16 years or over attending SHCs in England during 2011-2014 were included in the study. Individuals prescribed PEPSE were those who had a clinical record with the appropriate SHHAPT code. One hundred and twenty-six episodes (accounting for 78 attendees) of PEPSE were recorded after a HIV diagnosis-related SHHAPT code. These were assumed to be clinical coding errors and were excluded from further analysis. MSM were defined as men who had reported sex with another man (ie, their sexual orientation was self-reported as homosexual or bisexual) at least once during their clinic attendance history.
Data analysis
Trends in the number of episodes where PEPSE was prescribed were assessed using quarterly data between 2011 and 2014. The Kolmogorov-Smirnov test was used to compare the overall increase by year in the number of episodes where PEPSE was prescribed by gender/sexual risk. We used the British National Formulary price for a 28-day course of PEPSE (£772 in March 2016) to estimate the annual drug cost based on the number of episodes where PEPSE was prescribed.
Risk factors for being prescribed PEPSE were identified in the population of HIV-negative MSM attendees who were allocated to two groups based on their attendance history during 2011-2014: (i) those prescribed PEPSE and (ii) those not prescribed PEPSE. Demographic characteristics (age, ethnicity, country of birth and clinic location) were explored using the first recorded episode where PEPSE was prescribed or the first attendance for those not prescribed PEPSE. Ethnicity was defined by patient self-report and categorised based on the national Census codes. Country of birth was reported as International Organisation for Standardisation codes and categorised according to Office for National Statistics (UK) regions. We investigated the proportion of MSM diagnosed with an acute bacterial STI (chlamydia, gonorrhoea or infectious syphilis) in the year prior to and at their first recorded PEPSE episode or first attendance. Univariable and multivariable logistic regression were used to investigate demographic and clinical risk factors associated with PEPSE. Records with missing data on any of the variables were excluded (23 559 attendees out of a total of 253 496).
We used the Kaplan-Meier method to estimate the proportion of HIV-negative MSM attendees with a subsequent diagnosis code. To exclude incident HIV infections undiagnosed at the time of the PEPSE prescription, and to discount PEPSE failure, time at risk for HIV began 4 months after starting the most recent PEPSE course. This was based on the UK guidelines for PEPSE at the time (2011) which recommended follow-up HIV testing 12 weeks postcompletion of the PEPSE course. 5 Those not prescribed PEPSE were considered to be at risk from 4 months after their first attendance. MSM were censored at their HIV diagnosis or at the end of the follow-up period (30 September 2015). MSM whose first attendance was <4 months before the end of the follow-up period were excluded. Where no HIV code was reported, we assumed that MSM remained HIV negative regardless of whether they returned for a subsequent HIV test. Log rank tests were used to compare survival curves by the number of PEPSE courses prescribed and by the following risk profiles: 1. No PEPSE courses and no bacterial STI in the past 12 months 2. At least one PEPSE course and no bacterial STI in the past 12 months 3. No PEPSE courses and a bacterial STI in the past 12 months 4. At least one PEPSE course and a bacterial STI in the past 12 months Cox proportional hazards models were used to estimate HRs and to adjust for confounders (age, ethnicity, region of birth and clinic location). Records with missing data on any of the variables were excluded from the modelling (23 493 attendees out of a total of 252 257).
A sensitivity analysis was conducted to explore a more conservative censoring method; MSM were censored at their HIV diagnosis or the last HIV test. MSM with no subsequent HIV test were excluded from this sensitivity model resulting in a reduced study population of 88 431 (excluding 6332 with missing data).
RESULTS
During 2011-2014, there were 24 004 episodes where PEPSE was prescribed at SHCs in England: 16 422 (68%) were prescribed to MSM, 3333 (14%) were prescribed to heterosexual men and 3963 (17%) were prescribed to women. Sexual orientation was unknown for 283 (1%) episodes of PEPSE prescribed to men, and gender was unknown for 3 episodes.
The number of episodes where PEPSE was prescribed to MSM increased from 370 in the first calendar quarter (Q1) of 2011 to 1632 in Q4 of 2014, with the steepest increase between Q2 and Q3 of 2011 (70%). The overall increase in the number of episodes where PEPSE was prescribed by year was significantly greater for MSM (150%; 2382-5944) compared with heterosexual men (62%; 625-1104) and women (60%; 759-1212) ( p<0.001, Kolmogorov-Smirnov test) (figure 1). The estimated drug cost of PEPSE prescribing in 2014 was over £6 million per year, with £4.5 million attributable to MSM. There was a year-on-year increase in the proportion of all MSM attendees at SHCs who were prescribed PEPSE (2.01% in 2011 to 3.82% in 2014) (online supplementary table).
During 2011-2014, 13 453 MSM attendees were prescribed PEPSE. Fifteen per cent (1981) were prescribed more than one course; of these, 71% (1412) were prescribed two courses of PEPSE and 29% (569) three or more courses (maximum 13 courses). Among MSM prescribed more than one course, 60% (1194/1981) received a second course <6 months after the first course. The proportion of MSM attendees prescribed multiple courses (two or more) within a given calendar year did not change; 12.4% (254/2055) in 2011 compared with 9.9% (520/ 5282) in 2014.
Of MSM attendees prescribed PEPSE, 45% (6051/13 447) were aged 25-34 years, 80% (10 171/12 784) were white and 63% (7975/12 679) were born in the UK. Two-thirds (67%; 9033) were prescribed PEPSE at a London-based SHC. Fifty-four per cent (7229) had a prior attendance recorded at the same SHC since 2008, of which 83% (5960) had attended at least once in the previous year. This was higher than the prior attendance rate for MSM not prescribed PEPSE; 18% (44 004/ 240 043) had a prior attendance, of which 42% (18 506) had attended at least once in the previous year; 5.4% (725) of MSM prescribed PEPSE were diagnosed with at least one acute bacterial STI at the same attendance as the PEPSE prescription; 3.3% (443) were diagnosed with gonorrhoea, 2.1% (287) with chlamydia and <1% (57) with infectious syphilis; 10.8% (1446) of all MSM prescribed PEPSE had been diagnosed with at least one acute bacterial STI in the previous year; 7.2% (974) were diagnosed with gonorrhoea, 4.8% (648) with chlamydia and <1% (112) with infectious syphilis. Among all MSM not prescribed PEPSE, 11.8% (28 455) had at least one acute bacterial STI at their first attendance; 6.9% (16 642) were diagnosed with gonorrhoea, 5.1% (12 238) with chlamydia and 1% (2415) with infectious syphilis. Only 1.1% (2574) of all MSM not prescribed PEPSE had been previously diagnosed with at least one acute bacterial STI.
In the multivariable analysis, MSM prescribed PEPSE were more likely to be aged 25-44 years, be born outside of the UK, particularly sub-Saharan Africa (adjusted OR (aOR) (95% CI) 1.27 (1.13 to 1.43)) or the Caribbean (aOR (95% CI) 1.36 (1.08 to 1.72) (table 1), be of mixed (aOR (95% CI) 1.29 (1.17 to 1.41)) or black other (non-Caribbean/non-African) ethnicity (aOR (95% CI) 1.23 (1.01 to 1.51)) compared with white ethnicity, and to have attended a SHC in London (aOR (95% CI) 0.56 (0.53 to 0.58) for non-London versus London SHCs. MSM prescribed PEPSE were less likely to be diagnosed with an acute bacterial STI at the same attendance (aOR (95% CI)-gonorrhoea: 0.45 (0.40 to 0.50); chlamydia: 0.44 (0.39 to 0.50); syphilis: 0.51 (0.39 to 0.67)) but were more likely to have had a bacterial STI in the 12 months prior to the PEPSE prescription (aOR (95% CI)-gonorrhoea: 11.6 (10.5 to 12.8); chlamydia: 5.02 (4.46 to 5.67); syphilis: 2.25 (1.73 to 2.93)). The positive association between a previous bacterial STI diagnosis and PEPSE remained after adjusting for the number of prior attendances (data not shown).
Overall, 255 (1.9%) MSM attendees prescribed PEPSE and 1817 (0.8%) MSM not prescribed PEPSE were subsequently diagnosed with HIV with estimated HIV diagnosis rates of 9.7 per 1000 person-years (95% CI 8.6 to 11.0) and 3.0 per 1000 person-years (95% CI 2.8 to 3.1), respectively. The HIV diagnosis rate was considerably higher among MSM attendees who were prescribed two or more courses of PEPSE (18.2 per 1000 person-years (95% CI 14.1 to 23.6) compared with those prescribed one course (8.5 per 1000 person-years (95% CI 7.4 to 9.8) ( figure 2A and table 2A ). In the sensitivity analysis, MSM prescribed PEPSE had a HIV diagnosis rate of 38.5 per 1000 person-years (95% CI 34.0 to 43.5) compared with 13.6 per 1000 person-years (95% CI 12.9 to 14.2) among those not prescribed PEPSE. The HIV diagnosis rate for MSM prescribed two or more courses of PEPSE was 50.8 per 1000 person-years (95% CI 39.1 to 66.0) compared with 35.9 per 1000 personyears (95% CI 31.2 to 41.4) for MSM prescribed one course. This association was only weakly significant reflective of the smaller study population.
The probability of a HIV diagnosis varied according to risk profiles; MSM prescribed PEPSE and with a bacterial STI in the past 12 months had a considerably higher rate of HIV diagnosis (24.1 per 1000 person-years (95% CI 19.1 to 30.5) when compared with all other risk profiling groups (figure 2B). The HIV diagnosis rate was sixfold higher compared with those with the lowest risk profile (table 2B). In the sensitivity analysis, the same general trends were observed (data not shown).
DISCUSSION Main findings
The number of episodes where PEPSE was prescribed to MSM increased substantially and more rapidly than for heterosexual men and women. A total of 13 453 (4.5% overall) MSM attendees at SHCs in England during 2011-2014 were prescribed at least one episode of PEPSE and repeat prescribing was common (15% were prescribed two or more courses). MSM attendees diagnosed with a bacterial STI in the past 12 months were between 2 times and 12 times more likely to be prescribed PEPSE compared with those without a previous STI infection. Of note, MSM prescribed PEPSE, and in particular those prescribed two or more courses of PEPSE, were at high risk of subsequent HIV acquisition. 
Strengths and limitations
The strength of this study lies in the interrogation of national surveillance data with mandatory reporting from all specialist SHCs in England. The scale and detail of data using standardised reporting definitions are unprecedented and this study therefore provides a unique overview of PEPSE prescribing to inform clinical decision making and resource allocation.
This study has several limitations. First, although GUMCADv2 provides patient-level data, it is not possible to track patients between clinics. In a pilot study, 15% of MSM reported ever attending another SHC, 6 and this may be more common in urban settings like London, 7 which might lead to underestimation of HIV acquisition and repeat PEPSE prescribing in our study. Second, we have assumed that MSM were HIV negative until the end of follow-up time in the Kaplan-Meier analysis, unless they had a new HIV diagnosis, which might also underestimate HIV acquisition. However, the results of the sensitivity analysis, in which a more conservative approach was taken, were in accordance with the original model. Third, reporting of PEPSE prescribing was introduced in 2011 and there was an initial and expected lag phase in reporting such that overall PEPSE prescribing may be underestimated in our analysis during the early stages of 2011. However, we are confident that PEPSE coding was fully integrated into clinical practice by mid-2011, as implied by the fact that the trend lines for heterosexual males and females remain relatively stable after this time ( figure 1 ) and thus the impact is likely to be minimal. Fourth, sexual behaviour is strongly associated with both PEPSE use and HIV acquisition and the absence of these data limited our ability to interpret associations in our analyses. We used data on previous STI acquisition as a proxy measure for highrisk behaviour as this is a known predictor of HIV infection. 8 
Interpretation
We found a strong association between PEPSE use and a previous bacterial STI infection which suggests that MSM prescribed PEPSE represent a group with higher risk behaviours, as has been reported elsewhere. 9 10 The fact that MSM prescribed PEPSE were less likely to present with a bacterial STI at their attendance for PEPSE was expected, since PEPSE is provided within 72 hours of a sexual risk exposure when any STI is not likely to be detectable. MSM prescribed PEPSE were at high risk of HIV acquisition and the strong association between the number of PEPSE courses prescribed and the rate of HIV diagnosis suggests that PEPSE is a marker of ongoing risk behaviour. Several observational studies have reported HIV seroconversion after receiving PEPSE due to ongoing risk behaviour and re-exposure to HIV.
11-13 PEPSE use among a community cohort of MSM in Australia did not lead to a reduction in risk behaviour and those prescribed PEPSE had a higher rate of subsequent HIV seroconversion. 11 A retrospective review of MSM attending an urban health centre in Boston for PEPSE found no association between repeat PEPSE use and HIV infection risk compared with single PEPSE use, which differs from our results. However, the number of participants was smaller. 13 The association between a previous bacterial STI infection and HIV acquisition has been found elsewhere [14] [15] [16] and our study identified a particular subset of MSM prescribed PEPSE and with a previous bacterial STI that had the highest rate of HIV diagnosis.
Implications
In recent years, PEPSE use as an HIV prevention measure among MSM has increased and there is no indication that this will change. The overall cost is high (£4.5 million in MSM) despite the weak evidence base for its clinical effectiveness. 5 We have shown that PEPSE is a strong marker of subsequent risk behaviour and HIV acquisition among MSM attending SHCs and thus accessing a high standard of preventative care. In our analysis, 15% of MSM were prescribed PEPSE more than once at the same clinic and exhibited a fivefold increased risk of acquiring HIV infection despite receiving counselling and advice on risk reduction strategies. MSM prescribed PEPSE, and especially those returning for repeat PEPSE would benefit from more intensive risk reduction interventions. 1 Furthermore, national trends show a steadily increasing number of HIV diagnoses in MSM, and evidence from community-based surveys of sexual behaviour in MSM suggest that there is a need to enhance the existing HIV prevention package. Communitybased surveys have shown increases in UAI with casual partners, 16 17 self-reported STIs 16 and UAI with a main partner of a different HIV status. 18 A number of well-designed RCTs have demonstrated the very strong effectiveness of pre-exposure prophylaxis (PrEP) for preventing HIV infection among gay, bisexual and other MSM, 19 20 and support the inclusion of PrEP within a multicomponent HIV prevention package for MSM at risk, incorporating behavioural, structural and biomedical approaches based on robust scientific evidence. 21 In the deferred arm of the PROUD (Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection) study (ie, those who received PrEP after a deferral period of 1 year), PEPSE prescribing was common but HIV incidence was also very high. 19 Any HIV-PrEP programme is likely to be delivered through SHCs and reduce the number of MSM prescribed PEPSE and their subsequent risk of HIV acquisition. Furthermore, survey data suggest that MSM prescribed PEPSE are more likely to consider PrEP compared with those with no experience of PEPSE. 22 Of course, the value of PrEP is closely related to HIV incidence in various subgroups of the high-risk population and the cost savings that can be achieved, which is beyond the scope of this study.
Overall, we found that the number of episodes where PEPSE was prescribed has increased markedly in MSM, and that MSM attendees prescribed PEPSE are at sustained increased risk of acquiring HIV. This information is directly actionable, by supporting MSM who have been prescribed PEPSE to reduce sexual behavioural risk, and these MSM may be an appropriate group to target with PrEP. Biomedical interventions, like PrEP, in combination with other HIV prevention strategies including condom promotion, behavioural change and increased HIV testing may be beneficial for MSM that present for PEPSE, particularly those who have also been previously diagnosed with a bacterial STI.
Key messages
▸ Postexposure prophylaxis following sexual exposure (PEPSE) is a method to prevent HIV infection, but there are limited data on the surveillance and epidemiology of PEPSE prescribing at a national level. ▸ During 2011-2014, the number of episodes where PEPSE was prescribed increased markedly in men who have sex with men (MSM) compared with heterosexual men and women. ▸ MSM prescribed PEPSE, and in particular those prescribed two or more courses, are at high risk of subsequent HIV infection. ▸ These data might support clinical risk assessment decisions, including about the need for pre-exposure prophylaxis as part of a multicomponent HIV prevention package.
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